Orthocell\u00a0has shared that the first surgical case using\u202fRemplir\u2122 has been successfully completed within the U.S. Department of\u202fDefense\u202f(DoD) \/ Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply\u202fRemplir\u00a0into these hospital systems.<\/p>\n
This milestone marks the first clinical use of\u202fRemplir\u00a0within the DoD \/ VA network and represents an important step\u202fin\u202fOrthocell\u2019s\u202fU.S.\u202fcommercialisation\u202fstrategy,\u202fdemonstrating\u202fthe Company\u2019s ability to rapidly translate regulatory and procurement approvals into real\u2011world surgical adoption.\u202f The surgery was conducted at a military base hospital in Ohio.<\/p>\n
As announced on 15 April 2026,\u202fOrthocell\u202fsecured approval for\u202fRemplir\u00a0to be supplied across the U.S. Department of\u202fDefense\u202fand Veterans Affairs hospital networks, providing access to approximately 51 DoD military hospitals and 170 VA medical\u202fcentres\u202fnationwide.<\/p>\n
The rapid completion of a first surgical case highlights early engagement from surgeons within these systems and reinforces the strength of\u202fOrthocell\u2019s\u202fexisting U.S. distributor footprint, which spans 17 states and supports efficient onboarding and\u00a0in\u2011theatre\u00a0case support.\u202f\u00a0\u00a0These distributors will now support further uptake of\u00a0Remplir\u00a0across the DoD and VA systems as part of\u00a0Orthocell\u2019s\u00a0broader US commercialisation strategy.<\/p>\n
Orthocell\u00a0Managing Director Paul Anderson said: \u201cWe are extremely pleased to see\u202fRemplir\u202ftranslated into its first surgical case within the U.S. DoD and VA hospital network so quickly after receiving approval.\u202f\u00a0\u00a0It\u2019s a strong validation of our commercial strategy and surgeon engagement efforts while demonstrating the value of our distribution network.<\/p>\n <\/em>This milestone underscores both the clinical relevance of\u202fRemplir\u202ffor complex nerve injuries and our team\u2019s ability to execute rapidly once access is secured. Military and veteran healthcare systems manage some of the most challenging trauma cases, and early surgical uptake is an encouraging signal as we continue to expand activity across these hospitals.\u201d<\/em><\/p>\n The\u00a0initial\u00a0use of\u00a0Remplir\u00a0within the DoD \/ VA hospital network builds on\u00a0Orthocell\u2019s\u00a0broader rollout of\u00a0Remplir\u00a0across the U.S. hospital system and the strong commercialisation progress being achieved to date. With expanding hospital access, growing surgeon engagement and increasing case activity, the Company continues to make excellent progress with its\u00a0Remplir\u00a0rollout across the U.S.<\/p>\n Orthocell\u00a0will continue to work closely with its U.S. distribution partners and surgeon network to support further uptake of\u00a0Remplir\u2122 across the DoD and VA systems as part of its broader U.S. commercialisation strategy.<\/p>\n